InflaRx (IFRX) Depreciation & Amortization (CF) (2017 - 2026)
InflaRx's (IFRX) quarterly Depreciation & Amortization (CF) came in at $102067.9 in Q1 2026, down 14.73% year-on-year from $119705.5 in Q1 2025, and down 3.53% quarter-over-quarter from $105798.8 in Q4 2025.
InflaRx (IFRX) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
InflaRx has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $102067.9 for Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $102067.9, down 14.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $454705.6 (down 10.86% YoY), and the FY2025 annual result was $488296.5, down 5.81% from the prior year.
- Depreciation & Amortization (CF) came in at $102067.9 for Q1 2026 at InflaRx, down from $105798.8 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $172077.9 in Q1 2022 to a low of $102067.9 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $145824.3 (2023), against an average of $137828.6.
- Across the five-year window, Depreciation & Amortization (CF) decreased 23.6% in 2022 and increased 1.72% in 2023, its largest moves.
- InflaRx's Depreciation & Amortization (CF) stood at $151276.2 in 2022, then dropped by 3.6% to $145824.3 in 2023, then dropped by 18.85% to $118333.0 in 2024, then decreased by 10.59% to $105798.8 in 2025, then decreased by 3.53% to $102067.9 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $102067.9 (Q1 2026), $105798.8 (Q4 2025), and $116663.5 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1,395.22 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 429,663.65 |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | 102,067.95 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102,067.95 |
| Mar 31, 2026 | 102,067.95 |
| Dec 31, 2025 | 105,798.75 |
| Dec 31, 2025 | 105,798.75 |
| Sep 30, 2025 | 116,663.51 |
| Sep 30, 2025 | 116,663.51 |
| Jun 30, 2025 | 130,175.36 |
| Jun 30, 2025 | 130,175.36 |
| Mar 31, 2025 | 119,705.50 |
| Mar 31, 2025 | 119,705.50 |
| Dec 31, 2024 | 118,333.05 |
| Dec 31, 2024 | 118,333.05 |
| Sep 30, 2024 | 122,391.07 |
| Sep 30, 2024 | 122,391.07 |
| Jun 30, 2024 | 149,669.07 |
| Jun 30, 2024 | 149,669.07 |
| Mar 31, 2024 | 134,653.45 |
| Mar 31, 2024 | 134,653.45 |
| Dec 31, 2023 | 145,824.29 |
| Dec 31, 2023 | 145,824.29 |